Pharmaceuticals, Biotech & Life Sciences Brands · Advertiser / Brand
Johnson & Johnson
Large public healthcare manufacturer and commercial products company.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Johnson & Johnson
- Entity type
- COMPANY
- Founded
- 1887
- Headquarters
- United States
- Company size
- >5,000
- Market cluster / sector
- Pharmaceuticals, Biotech & Life Sciences Brands
- Market role
- Advertiser / Brand
- Ticker
- JNJ
- Official website
- jnj.com
What Johnson & Johnson does
The company creates value by developing, manufacturing, and distributing healthcare products at global scale. It monetises through product sales across professional healthcare and commercial channels, using its operating scale, brand equity, regulatory capabilities, and distribution relationships to generate recurring revenue.
Category differentiation
This is the public healthcare corporation, not an adtech, martech, or software platform. It should not be confused with any specific product brand, healthcare subsidiary, or unrelated Johnson-branded business.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Johnson & Johnson is a long-established public healthcare company. Based on the company name and widely established market identity, it operates as a large manufacturer and commercialiser of healthcare products, with revenue generated through the sale of medical, pharmaceutical, and consumer health-related products via healthcare channels and commercial distribution networks. The provided input confirms only that the company is active, founded in 1887, and operates at substantial scale with more than 5,000 employees and more than 1 billion in revenue. Because no product-level or customer-level extraction was supplied, customer and monetisation detail below is necessarily expressed at a high level.
Company news briefing
Briefing updated:
Following its Q3 2026 financial reporting, Johnson & Johnson recorded strong customer sales growth driven by Oncology and MedTech, despite a sharp decline in consolidated net earnings caused by a proposed $5.5 billion talc litigation settlement and R&D charges. The healthcare giant continues to advance its clinical pipeline, releasing positive long-term data for ICOTYDE in plaque psoriasis, TREMFYA in axial psoriatic arthritis, and RYBREVANT in lung cancer. Additionally, the firm maintains strategic AI drug discovery partnerships, such as its ongoing collaboration with Isomorphic Labs.
Business model & monetisation
Primarily product-sales driven revenue from manufactured healthcare goods sold through commercial and healthcare distribution. The exact mix between pharmaceutical, medical technology, and consumer categories is not specified in the provided inputs, so pricing mechanisms cannot be broken down more precisely here.
Products & capabilities
No products with linked sources are available in this view.
POLARIS7 WORKSPACE
Go deeper on Johnson & Johnson and its market context
Access extended corporate structures, historical M&A and partnership links, technical footprint data, and automated Watchlist briefings grounded in primary sources.
- Corporate & subsidiary hierarchy
- Competitor & partner network
- Automated Watchlist briefings
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Johnson & Johnson's competitive landscape.
Global pharmaceutical company selling medicines and vaccines.
Diversified life sciences company spanning pharmaceuticals, consumer health and agriculture.
Biopharmaceutical company developing and commercialising prescription medicines.
Global medical device and healthcare technology manufacturer.
Public consumer healthcare brand owner focused on everyday health.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Johnson & Johnson Furnishes Q3 2026 Earnings Announcement via Current Report
financials · Recorded impact score: 4.5/5
Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.
- Worldwide sales reached $25.40 billion in Q3 2026 (+5.9% YoY) and $74.77 billion for the first nine months (+7.4% YoY), supported by gains in DARZALEX ($4.24 billion in Q3) and TREMFYA ($2.40 billion in Q3).
- Net earnings plummeted to $210 million in Q3 2026 due to a $5.5 billion litigation charge to resolve ovarian talc claims and a $1.0 billion acquired IPR&D charge for Firefly Bio, Inc.
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Product & Platform Launch · Recorded impact score: 4/5
Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
Product & Platform Launch
Johnson & Johnson announced on September 25, 2026, that TREMFYA (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in a landmark axial psoriatic arthritis (PsA) study. Topline results met the primary and major secondary endpoints, including MRI-confirmed inflammation reduction. This is the first study to use objective MRI assessments to confirm axial involvement and demonstrate its reduction in PsA.
- On September 25, 2026, Johnson & Johnson announced topline results from a landmark axial psoriatic arthritis (PsA) study.
- TREMFYA (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in axial PsA.
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Product & Platform Launch · Recorded impact score: 3/5
Johnson & Johnson published a behind-the-scenes feature on September 25, 2026, highlighting how the company manufactures and delivers CAR-T cell therapy for multiple myeloma. The article focuses on the complexity of producing and distributing this personalized cancer treatment. No specific clinical data, product names, or commercial terms are disclosed in the provided text.
- Johnson & Johnson published a behind-the-scenes feature on September 25, 2026.
- The article focuses on Johnson & Johnson's CAR-T cell therapy manufacturing and delivery for multiple myeloma.
New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026
Product & Platform Launch · Recorded impact score: 4/5
Johnson & Johnson announced new overall survival data and treatment experience improvements for RYBREVANT-based regimens in EGFR-mutated lung cancer at WCLC 2026. Final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC will be featured in a Presidential Symposium. Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO and prophylactic strategies.
- Published on September 11, 2026.
- Final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC to be presented at Presidential Symposium at WCLC 2026.
Careers & open positions
Open positions indexed from verified career portals and applicant tracking systems.
| Position | Department | Location | Posted |
|---|---|---|---|
| District Account Manager- Biosurgery Specialist(Mid-Level) | MedTech Sales | Ludhiana | |
| District Manager, Oncology- Srinagar(Manager) | Pharmaceutical Sales | Gurgaon | |
| Manager, Site Services(Manager) | Environmental Health, Safety (EH&S) and Facilities Services (FS) | Chiyoda | |
| (高级)地区经理-皮科产品业务部-北京(Senior) | Pharmaceutical Sales | Beijing | |
| SOX 404 Analyst(Mid-Level) | Finance | Taguig City, Metro Manila |
Explore company relationships
Questions about Johnson & Johnson
What is Johnson & Johnson?
Johnson & Johnson is a large public healthcare company with a long operating history and substantial global scale.
Who uses Johnson & Johnson?
Its products are used by healthcare providers, institutions, distributors, retailers, pharmacies, and consumers, depending on the product category.
How does Johnson & Johnson make money?
It primarily makes money by selling healthcare products through professional and commercial distribution channels.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
5 publicly documented primary sources and citations linked across the market graph.
Start with a company or market. Track what changes.
Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.
Johnson & Johnson
Open extended company details, ownership links, and automated signal monitoring in Polaris7.
